{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:20:04Z","timestamp":1764757204667,"version":"3.46.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"DOI":"10.7759\/cureus.98359","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:18:36Z","timestamp":1764757116000},"source":"Crossref","is-referenced-by-count":0,"title":["Tezepelumab After Mepolizumab in Allergic Bronchopulmonary Mycosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Naohiro","family":"Oda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Takeguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reo","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.029","article-title":"New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation","volume":"147","author":"Asano K","year":"2021","unstructured":"Asano K, Hebisawa A, Ishiguro T, et al.. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation. J Allergy Clin Immunol. 2021, 147:1261-8.e5. 10.1016\/j.jaci.2020.08.029","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00061-2024","article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses","volume":"63","author":"Agarwal R","year":"2024","unstructured":"Agarwal R, Sehgal IS, Muthu V, et al.. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses. Eur Respir J. 2024, 63:2400061. 10.1183\/13993003.00061-2024","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.12.012","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis","volume":"11","author":"Jin M","year":"2023","unstructured":"Jin M, Douglass JA, Elborn JS, et al.. Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023, 11:896-905. 10.1016\/j.jaip.2022.12.012","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32246-8","article-title":"Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis","volume":"13","author":"Tomomatsu K","year":"2023","unstructured":"Tomomatsu K, Yasuba H, Ishiguro T, et al.. Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis. Sci Rep. 2023, 13:5468. 10.1038\/s41598-023-32246-8","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2022.101723","article-title":"Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: a case report","volume":"39","author":"Kai Y","year":"2022","unstructured":"Kai Y, Yoshikawa M, Matsuda M, et al.. Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: a case report. Respir Med Case Rep. 2022, 39:101723. 10.1016\/j.rmcr.2022.101723","journal-title":"Respir Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42464","article-title":"A case of allergic bronchopulmonary aspergillosis with failure of benralizumab and response to dupilumab","volume":"15","author":"Kotetsu Y","year":"2023","unstructured":"Kotetsu Y, Ogata H, Sha K, Moriwaki A, Yoshida M. A case of allergic bronchopulmonary aspergillosis with failure of benralizumab and response to dupilumab. Cureus. 2023, 15:e42464. 10.7759\/cureus.42464","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata H","year":"2023","unstructured":"Ogata H, Sha K, Kotetsu Y, et al.. Tezepelumab treatment for allergic bronchopulmonary aspergillosis. Respirol Case Rep. 2023, 11:e01147. 10.1002\/rcr2.1147","journal-title":"Respirol Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.05.026","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab","volume":"11","author":"Matsuno O","year":"2023","unstructured":"Matsuno O. Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab. J Allergy Clin Immunol Pract. 2023, 11:2589-91. 10.1016\/j.jaip.2023.05.026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S541770","article-title":"Three biologic-na\u00efve patients with allergic bronchopulmonary aspergillosis showing significant clinical improvement with tezepelumab","volume":"18","author":"Yamaguchi M","year":"2025","unstructured":"Yamaguchi M, Yamazaki A, Nakagawa H, Kinose D, Nakano Y. Three biologic-na\u00efve patients with allergic bronchopulmonary aspergillosis showing significant clinical improvement with tezepelumab. J Asthma Allergy. 2025, 18:1221-7. 10.2147\/JAA.S541770","journal-title":"J Asthma Allergy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya R","year":"2023","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023, 23:24-37. 10.1038\/s41577-022-00735-y","journal-title":"Nat Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.2.1080","article-title":"TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells","volume":"179","author":"Kato A","year":"2007","unstructured":"Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol. 2007, 179:1080-7. 10.4049\/jimmunol.179.2.1080","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211047003","article-title":"Review of current and future therapeutics in ABPA","volume":"12","author":"Lewington-Gower E","year":"2021","unstructured":"Lewington-Gower E, Chan L, Shah A. Review of current and future therapeutics in ABPA. Ther Adv Chronic Dis. 2021, 12:20406223211047003. 10.1177\/20406223211047003","journal-title":"Ther Adv Chronic Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.048","article-title":"Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus","volume":"141","author":"Muniz VS","year":"2018","unstructured":"Muniz VS, Silva JC, Braga YA, et al.. Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus. J Allergy Clin Immunol. 2018, 141:571-85.e7. 10.1016\/j.jaci.2017.07.048","journal-title":"J Allergy Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren J","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017, 377:936-46. 10.1056\/NEJMoa1704064","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark LH","year":"2023","unstructured":"Nordenmark LH, Hellqvist \u00c5, Emson C, et al.. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023, 2:EVIDoa2300135. 10.1056\/EVIDoa2300135","journal-title":"NEJM Evid"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro M","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al.. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018, 378:2486-96. 10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.06.006","article-title":"Paradoxical effects of dupilumab in allergic bronchopulmonary aspergillosis: resolution of mucus plugging but induction of eosinophilic pneumonia","volume":"135","author":"Matsuno O","year":"2025","unstructured":"Matsuno O, Wibowo T, Ishida Y, Ogata A. Paradoxical effects of dupilumab in allergic bronchopulmonary aspergillosis: resolution of mucus plugging but induction of eosinophilic pneumonia. Ann Allergy Asthma Immunol. 2025, 135:588-9. 10.1016\/j.anai.2025.06.006","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440728-tezepelumab-after-mepolizumab-in-allergic-bronchopulmonary-mycosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:18:36Z","timestamp":1764757116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440728-tezepelumab-after-mepolizumab-in-allergic-bronchopulmonary-mycosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.98359","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}